---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-110166"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:47:31.014436+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet opens Phase 1 enrollment for ADI-001 in autoimmune diseases; preliminary data expected H1 2025

## Summary
- Phase 1 trial now enrolling lupus nephritis (LN) patients; SLE, SSc, AAV enrollment to open Q4 2024.
- FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III/IV LN.
- Plan to report preliminary clinical data in LN, SLE, SSc, and AAV by first half of 2025.
- Trial has three arms: LN/SLE, SSc, AAV; single dose of ADI-001 with 28-day DLT window and 24-month follow-up.

## SEC filing metadata
- accession: 0000950170-24-110166
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024110166/0000950170-24-110166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024110166/acet-20240930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-110166
- JSON: https://secwatch.observer/filing/0000950170-24-110166.json
- Plain text: https://secwatch.observer/filing/0000950170-24-110166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.